A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab

GlaxoSmithKline135 enrolled

Overview

The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Korean postmenopausal women with osteoporosis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

135

Conditions

Osteoporosis, Postmenopausal

Interventions

denosumabDRUG

double-blind phase: 60mg subcutaneous injection, single dose

placeboDRUG

double-blind phase: placebo subcutaneous injection, single dose

open-label denosumabDRUG

open-label phase: 60mg subcutaneous injection, single dose

Eligibility

Sex: FEMALEMin age: 60 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Ambulatory Korean postmenopausal women with osteoporosis * greater than 5 years postmenopausal * aged 60 to 90 years old * absolute bone mineral density value consistent with a T-score less than -2.5 and greater than or equal to - 4.0 at the either the lumbar spine or total hip, as measured by dual energy x-ray absorptiometry. Subjects with a T-score less than -4.0 are at very high risk for fracture and will be excluded. Exclusion Criteria: * previous or current metabolic bone disease, Paget's or Cushing's disease, or hyperprolactinemia * current hypo- or hyperparathyroidism or hypo- or hyperthyroidism unless on stable thyroid replacement therapy and TSH level meets criteria * rheumatoid arthritis * cirrhosis of the liver or unstable liver disease or ALT or AST greater than or equal to 2.0 times the upper limit of normal, or alkaline phosphatase and bilirubin greater than or equal to 1.5 times the upper limit of normal * medications used to treat osteoporosis, defined for type and duration of use, and including IV and oral bisphosphonates * medications that affect bone metabolism including parathyroid hormone or derivatives; anabolic steroids or testosterone; glucocorticosteroids; systemic hormone replacement therapy; selective estrogen receptor modulators; tibolone, calcitonin, and calcitriol or vitamin D derivatives; other bone active drugs including anticonvulsives (but not benzodiazepines) and heparin; chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, and gonadotropin-releasing hormone agonists * malignancy within 5 years except certain resected types * malabsorption syndrome or gastrointestinal disorders associated with malabsorption * abnormal calcium level * vitamin D deficiency * any laboratory abnormality that will prevent the subject from completing the study or interfere with interpretation of study results * severe renal impairment or on dialysis * impaired immune system or subject is taking immunosuppressants * oral or dental conditions including current or past history of osteomyelitis or osteonecrosis of the jaw; active dental or jaw condition with requires oral surgery; planned invasive dental procedure; un-healed dental or oral surgery * any disorder that compromises the ability of the subject to give written informed consent or to comply with study procedures * any physical or psychiatric disorder that will prevent the subject from completing the study or interferes with study results * known to have tested positive for HIV * less than two lumbar vertebrae evaluable for DXA measurements * height, weight, or girth that may preclude accurate DXA measurements * drug or alcohol abuse within 12 months that interferes with understanding or completing the study * known sensitivity to mammalian cell-derived drug products * use of an investigational drug or device within 30 days of enrollment or currently receiving other investigational agent(s)

Locations (10)

GSK Investigational Site

Busan, South Korea

GSK Investigational Site

Daegu, South Korea

GSK Investigational Site

Gwangju, South Korea

GSK Investigational Site

Seoul, South Korea

Outcomes

Primary Outcomes

Mean Percent Change From Baseline in Lumbar Spine BMD at Month 6

Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using the Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 6 - measure at Baseline) divided by the measure at Baseline \* 100.

Time frame: Baseline and Month 6

Secondary Outcomes

Mean Percent Change From Baseline in Lumbar Spine BMD at Month 1

Mean percent change from Baseline in lumbar spine bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covariance (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 1 - measure at Baseline) divided by the measure at Baseline \* 100.

Time frame: Baseline and Month 1

Mean Percent Change From Baseline in Total Hip, Femoral Neck, and Trochanter BMD at Month 1 and Month 6

Mean percent change from Baseline in total hip, femoral neck, and trochanter bone mineral density (BMD) was measured by the dual-energy x-ray absorptiometry (DXA) scanner. Analyses were performed using Analysis of Covarience (ANCOVA) model adjusting for treatment and Baseline BMD for the skeletal site under consideration as a continuous covariate. Percentage change from Baseline=(measure at Month 1/6 - measure at Baseline) divided by the measure at Baseline \* 100.

Time frame: Baseline, Month 1 and Month 6

Median Percent Change From Baseline in s-CTX and s-P1NP Biomarkers at Months 1, 3 and 6

Serum carboxy-terminal cross-linking telopeptide of type I collagen (s-CTx) I and Serum procollagen type I N propeptide s (s-PINP) are used as serum biomarkers of bone resorption in the assessment of osteoporosis and is measured in units of micrograms (µg)/liters (L). Percentage change from Baseline=(measure at post-Baseline - measure at Baseline) divided by measure at Baseline \* 100.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.